The British Business Bank put £15m into a $133m Series B for T-Therapeutics, a University of Cambridge spinout, announced on Thursday 5 November. Advent Life Sciences and the Bank co-led the round, and the Bank takes a board seat1. The Bank calls it its third co-investment beside Advent, and it also holds an indirect stake through Cambridge Innovation Capital's second fund2. Eli Lilly, Johnson & Johnson Innovation, Samsara BioCapital and M Ventures, the venture arm of Germany's Merck KGaA, joined; existing backers including Sofinnova Partners returned3.
The money takes two T-cell receptor bispecifics towards clinical proof of concept, one in cancer and one in autoimmune disease. Each molecule grips a marker on a diseased cell with one arm and pulls in a T cell, the immune system's killer cell, with the other. The Bank led Microbiotica's round in October and followed in OMass's; with T-Therapeutics it is co-leading and sitting on the board.
